Avista Pharma Adds to API Manufacturing Capacity
Avista Pharma Solutions, a Durham, North Carolina-headquartered contract testing, development, and manufacturing organization, has completed facility upgrades that the company says will double the its active pharmaceutical ingredient (API) manufacturing capacity at its Longmont, Colorado site.
During this expansion, the site’s three existing GMP drug-substance manufacturing suites were upgraded and a fourth GMP suite was added. The facility’s non-GMP capacity was also doubled with the addition of two large-scale development suites.
Among the new equipment installations were four walk-in hoods, three 50-gallon glass-lined reactors, three Hastelloy agitated filter dryers, and various small-scale reactors and mixing vessels. The new equipment will provide additional scale and enable processing of complex and potent categories of chemical compounds.
Safety and containment controls were also upgraded during the expansion, which gives Avista the ability to manufacture materials rated up to occupational exposure bands of 3A and 3B.
The API facility expansion is one of several investments at the Longmont site during 2017. Avista Pharma is also in the process of expanding its drug-product manufacturing capacity and analytical capacity as well as adding walk-in stability storage chambers into the additional 20,000-square-foot expansion announced in 2016.
Source: Avista Pharma Solutions